ClinicalTrials.gg
Not yet recruitingNCT05843162PRISTINEUpdated May 6, 2023

A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome

A Phase 4 interventional study of Telmisartan and Losartan in Essential Hypertension and Metabolic Syndrome, sponsored by Chong Kun Dang Pharmaceutical. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical — 2 open to participants now, 2 under way, 1 of them phase 3. Essential Hypertension · Chong Kun Dang Pharmaceutical.

Planned enrollment
10th of 17
116 · median 169
Started
2023
with 2 others
Phase 4
2 of 18
1 open now
Registered
15th of 18
by date

Among the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 4, and was the 15th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, or all of them as a file.
02

Study summary

This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome

Read the detailed description

Participants were randomly assigned in a 1:1 ratio to the following group; the test group [Telmisartan 40 mg + S-Amlodopine 2.5 mg], the control group [Losartan 50 mg + S-Amlodopine 2.5 mg]. If the blood pressure measured at 6 weeks time (Visit 3) based on the random allocation date (Visit 2) is MSSBP ≥140 mmHg or MSDBP ≥90 mmHg, the test group will increase the Telmisartan 80 mg, the control group will increase the dose to 100 mg for 6 weeks from Visit 3 to Visit 4(End of study). However, if the need of dose increasing is not required according to the investigator's judgment, the current dose can be maintained. All clinical trial drugs are administered orally once a day, and it is recommended to be administered at the same time(am) for 12 weeks.

03

Conditions studied

  • Essential Hypertension
  • Metabolic Syndrome
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[Screening/Run-in period (Visit 1)]

  • Adults over 19 years of age
  • Patients who have been diagnosed with essential hypertension or who are taking antihypertensive drugs after diagnosis (However, if you are already taking antihypertensive drugs, you can discontinue/change the antihypertensive drugs and agree to this)
  • At the time of screening/introduction (Visit 1), the following metabolic syndrome diagnosis criteria ①\~④ satisfy ① fasting blood glucose standards, and those who meet at least one of ②\~④ criteria (① Fasting blood sugar: ≥100 mg/dL or a state in which medication is being administered to control blood sugar, ② Waist circumference: male ≥90 cm, female ≥85 cm, ③ HDL-cholesterol: male \<40 mg/dL, female \<50 mg/dL or taking medication to increase HDL-cholesterol, ④ Triglyceride: ≥150 mg/dL or taking medication to lower triglyceride)

[Randomization (Visit 2)]

  • Patients whose average sitting systolic or diastolic blood pressure measured in the arm selected as the reference arm during the screening test at the time of randomization (Visit 2) corresponds to the following

    • 140 mmHg ≤ mean sitting systolic blood pressure (MSSBP) \< 180 mmHg
    • 90 mmHg ≤ mean sitting diastolic blood pressure (MSDBP) \< 110 mmHg
  • At the time of randomization (Visit 2), the following metabolic syndrome diagnosis criteria ① to ④ satisfy ① fasting blood sugar criteria, and those who meet at least one of ② to ④ criteria (① Fasting blood sugar: ≥100 mg/dL or a state in which medication is being administered to control blood sugar, ② Waist circumference: male ≥90 cm, female ≥85 cm, ③ HDL-cholesterol: male \<40 mg/dL, female \<50 mg/dL or taking medication to increase HDL-cholesterol, ④ Triglyceride: ≥150 mg/dL or taking medication to lower triglyceride)

Exclusion criteria

Exclusion Criteria:

  • Patients whose blood pressure measured at the time of screening/introduction (Visit 1) corresponds to any of the following

    • Patients with MSSBP ≥180 mmHg or MSDBP ≥110 mmHg
    • Patients with MSSBP ≥20 mmHg and MSDBP ≥10 mmHg difference in blood pressure measured 3 times in each arm
  • Patients with a history of secondary hypertension or suspected secondary hypertension (aortic coarctation, hyperaldosteronemia, renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.)
  • Patients with orthostatic hypotension with symptoms
  • Patients with type 1 diabetes or poorly controlled diabetes ( >9.0%)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Telmisartan

    Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg

    Drug: Telmisartan

  • Active comparator
    Losartan

    Cozaar Tab.(Losartan) 50mg(100mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg

    Drug: Losartan

Interventions

  • Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.

  • Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.

06

What researchers measure

Primary outcomes

  1. MSSBP change

    MSSBP change between administration groups after 12 weeks (Visit 4) compared to baseline (Visit 2)

    Time frame: Baseline (Visit 2), 12 weeks (Visit 4)

Secondary outcomes

  1. MSSBP change

    MSSBP change between administration groups after 6 weeks (Visit 3) compared to baseline (Visit 2)

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3)

  2. MSDBP change

    MSDBP change between administration groups compared to baseline (Visit 2) after 6 weeks (Visit 3) and 12 weeks (Visit 4)

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

  3. Blood pressure normalization ratio

    Blood pressure normalization ratio (ratio of subjects with MSSBP \<140 mmHg and MSDBP \<90 mmHg) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

  4. Blood pressure response rate

    Blood pressure response rate (MSSBP reduction ≥20 mmHg and MSDBP reduction ≥10 mmHg) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between treatment groups

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

  5. Changes in HOMA-IR

    Changes in HOMA-IR\[(Fasting insulin(mU/L)×Fasting glucose(nmol/L))/22.5\]

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

  6. Changes in HOMA-β

    Changes in HOMA-β\[(20×Fasting insulin(mU/L))/(Fasting glucose(nmol/L)-3.5)\]

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

  7. Changes in Glucose

    Changes in Glucose(nmol/L)

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

  8. Changes in Insulin

    Changes in Insulin(mU/L) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

  9. Changes in HbA1c

    Changes in HbA1c (%) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups

    Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Dec 2023, 6 months later.

Of 22 phase 4 interventional studies under Essential Hypertension, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 36. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
May 6, 2023
StartEst.
Jun 1, 2023
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843162
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jun 1, 2023 (estimated)
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
May 6, 2023

Study contacts

Soo Lee, MD
Contact
limsoo@snu.ac.kr
82-31-787-7035
Soo MD, MD
principal investigator · Seoul National University Bundang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion